Article Text
Prevalence
Cross-sectional
Severe adverse reactions are rare with infusions of infliximab in a community setting
Statistics from Altmetric.com
Footnotes
-
Competing interests YY has been a consultant or speaker for BMS, Celgene, Centocor, Genentech, Merck, Pfizer, Roche and UCB.